Ebola drugs show ‘90% survival rate’ in breakthrough trial
- Published
An outbreak of Ebola has killed more than 1,800 people in the Democratic Republic of Congo
Ebola may soon be a "preventable and treatable" disease after a trial of two drugs showed significantly improved survival rates, scientists have said.
Four drugs were trialled on patients in the Democratic Republic of Congo, where there is a major outbreak of the virus.
More than 90% of infected people can survive if treated early with the most effective drugs, the research showed.
The drugs will now be used to treat all patients with the disease in DR Congo, according to health officials.
On Tuesday, two people cured of Ebola using the experimental drugs were released from a treatment centre in Goma, eastern DR Congo, and reunited with their families.
The US National Institute of Allergy and Infectious Diseases (NIAID), which co-sponsored the trial, said the results are "very good news" for the fight against Ebola.
The drugs, named REGN-EB3 and mAb114, work by attacking the Ebola virus with antibodies, neutralising its impact on human cells.
They are the "first drugs that, in a scientifically sound study, have clearly shown a significant diminution in mortality" for Ebola patients, said Dr Anthony Fauci, director of NIAID.
The drug mAb114 was developed using antibodies harvested from survivors of Ebola while REGN-EB3 comes from antibodies generated within mice infected with the disease.
Ebola has killed more than 1,800 people in DR Congo in the past year.
Two other treatments, called ZMapp and Remdesivir, have been dropped from trials as they were found to be less effective.
What were the results of the trial?
The trial, conducted by an international research group co-ordinated by the World Health Organization (WHO), began in November last year.
Since then, four experimental drugs have been tested on around 700 patients, with the preliminary results from the first 499 now known.
Health workers dressed in protective suits disinfect an ambulance at an Ebola treatment centre in DR Congo
Of the patients given the two more effective drugs, 29% on REGN-EB3 and 34% on mAb114 died, NIAID said.
In contrast, 49% on ZMapp and 53% on Remdesivir died in the study, the agency said.
The survival rate among patients with low levels of the virus in their blood was as high as 94% when they were given REGN-EB3, and 89% when on mAb114, the agency said.
The findings mean health authorities can "stress to people that more than 90% of people survive" if they are treated early, said Sabue Mulangu, an infectious-disease researcher who worked on the trial.
What impact could the drugs have?
Hailing the success of the study, Jeremy Farrar, director of the Wellcome Trust global health charity, said the treatments would "undoubtedly save lives".
The findings, Mr Farrar said, indicate scientists are getting closer to turning Ebola into a "preventable and treatable" disease.
Fear and myths: Why people are still in denial about Ebola
"We won't ever get rid of Ebola but we should be able to stop these outbreaks from turning into major national and regional epidemics," he added.
A sense that Ebola is incurable, paired with widespread mistrust of medical workers in the DR Congo, has hampered efforts to stop the spread of the disease.
It is hoped that the effectiveness of the drugs, made by US-based pharmaceutical firms, will make patients feel "more comfortable about seeking care early", said Dr Fauci.
But the best way to end the outbreak, he added, is "with a good vaccine". A vaccine is a type of medicine that improves immunity to a particular disease, as a preventative measure.
The World Health Organization (WHO) say vaccines developed to protect against Ebola, which are allowed for "compassionate use" before official licensing, have proven highly effective.
How serious is the DR Congo outbreak?
The current outbreak in eastern DR Congo began in August last year and is the biggest of the 10 to hit the country since 1976, when the virus was first discovered.
But it is dwarfed by the West African epidemic of 2014-16, which affected 28,616 people, mainly in Guinea, Liberia and Sierra Leone. About 11,310 people died in what was the largest outbreak of the virus ever recorded.
Congolese health workers prepare to administer Ebola vaccinations
However, attempts to contain the latest outbreak are proving difficult. In particular, militia group violence and suspicion towards foreign medical assistance have hindered efforts.
Earlier this month, three Congolese doctors were arrested in DR Congo over the killing of a WHO medic.
About 200 health facilities have been attacked in the country this year, causing disruption to vaccinations and treatments. In one incident, family members assaulted health workers who were overseeing the burial of their relative.
A 2018 study published in the Lancet medical journal says "belief in misinformation was widespread" concerning the Ebola outbreak.
What is Ebola?
Ebola is a virus that initially causes sudden fever, intense weakness, muscle pain and a sore throat
It progresses to vomiting, diarrhoea and both internal and external bleeding
People are infected when they have direct contact through broken skin, or the mouth and nose, with the blood, vomit, faeces or bodily fluids of someone with Ebola
Patients tend to die from dehydration and multiple organ failure
- Published4 August 2019
- Published8 August 2019
- Published2 August 2019
